A major international review has cast doubt on a new generation of Alzheimer’s treatments that many hoped would slow the disease, finding they offer little meaningful benefit for patients while carrying notable risks.
The analysis, led by the Cochrane Collaboration, examined 17 clinical trials involving more than 20,000 people with early-stage Alzheimer’s disease or mild cognitive impairment. These trials focused on anti-amyloid drugs, designed to remove amyloid beta proteins from the brain – long believed to play a central role in the disease.
While the drugs were effective at clearing these proteins, the review found the real-world impact on patients was minimal.
Lead author Francesco Nonino said the results point to a clear conclusion: although some trials showed statistically significant changes, they did not translate into noticeable improvements in memory, thinking, or daily function.
“Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” he said.
The findings showed only very small improvements across standard measures of cognition and dementia severity – changes so minor they are unlikely to be noticed by patients or their families in everyday life.
At the same time, the drugs were linked to increased risks, including brain swelling and bleeding. In many cases, these side effects were detected on scans rather than through symptoms, but experts say the long-term implications remain uncertain.
Professor Bryce Vissel from the University of New South Wales described the findings as “sobering,” particularly given the hope these treatments have generated.
“These drugs clear plaques far more convincingly than they preserve memory, thinking and independence,” he said.
For decades, Alzheimer’s research has been guided by the “amyloid hypothesis” – the idea that removing amyloid plaques could slow or stop the disease. These drugs were developed specifically to target that process.
But the latest evidence suggests the relationship between amyloid and symptoms may not be as straightforward as once thought.
“This review forces a blunt question,” Vissel said. “If these drugs remove the very plaques long thought to drive Alzheimer’s, why are patients not improving in meaningful ways?”
Despite the disappointing findings, experts stress this is not the end of Alzheimer’s research – far from it.
Dr Nikki-Anne Wilson said the results highlight the need to look beyond a single treatment pathway and focus on broader approaches to brain health.
“The brain is complex, and a single mechanism is unlikely to offer the magic bullet we seek,” she said.
She pointed to growing evidence that lifestyle factors – such as exercise, diet, and managing cardiovascular health – can play a significant role in reducing dementia risk and slowing progression.
Professor Amy Brodtmann added that while the conclusions may be contentious, they provide important guidance for clinicians and patients navigating treatment decisions.
For families affected by Alzheimer’s, the findings may feel like a setback after years of anticipation around new therapies.
But experts emphasise that understanding what doesn’t work is just as important as discovering what does.
The focus now is shifting toward more personalised and multi-faceted approaches – targeting not just one protein, but the broader processes affecting brain cells and connections.
As Vissel put it: “No therapy can be called disease-modifying unless it delivers real improvements in quality of life.”
For now, that remains the goal—and the challenge—for researchers around the world.